OmniAb (NASDAQ: OABI) outlines 2026 guidance after lower 2025 revenue
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.
Positive
- None.
Negative
- None.
Insights
Revenue declined but guidance, pipeline breadth and cost discipline frame a stabilizing story.
OmniAb’s 2025 revenue dropped to $18.7 million from $26.4 million, reflecting fewer license, milestone and service revenues as legacy ion channel work tapered. Despite this, the company expanded to 107 active partners and 407 active programs, including 32 in clinical or commercial stages.
Operating structure is shifting toward a leaner model. Research and development fell to $47.8 million and general and administrative to $29.2 million, although results included a $3.9 million impairment. Ending cash of $54.0 million and a 2026 non‑GAAP cash cost target of $50–$55 million imply a continued cash burn that narrows if revenue reaches the guided $25–$30 million range.
Guidance for year-end 2026 cash of $30–$35 million and an effective tax rate near 0% suggests management expects ongoing losses but manageable liquidity through at least 2026. Progress of partner programs like IMVT‑1402, batoclimab, TEV‑'408 and precemtabart tocentecan, along with uptake of OmniUltra and xPloration, will be key drivers of future milestone and royalty revenue as disclosed timelines into 2027 unfold.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 04, 2026
(Exact Name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
(510 ) 250-7800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On March 4, 2026, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | ||||
99.1 | Press release dated March 4, 2026. | ||||
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OMNIAB, INC. | ||||||||
Date: March 4, 2026 | By: | /s/ Kurt Gustafson | ||||||
| Name: Kurt Gustafson | ||||||||
| Title: Executive Vice President, Finance and Chief Financial Officer | ||||||||
Exhibit 99.1
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Conference Call Begins at 4:30 p.m. Eastern Time Today
EMERYVILLE, Calif. (March 4, 2026) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates.
“OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue,” said Matt Foehr, Chief Executive Officer of OmniAb. "Our focus on innovation was evident in the recent launch of OmniUltra™, which strengthens our ability to attract new partners and service new programs. Additionally, we continue to see strong interest in the xPloration partner access program and are excited about its contributions to the business.”
Fourth Quarter 2025 Financial Results
Revenue for the fourth quarter of 2025 was $8.4 million, compared with $10.8 million for the same period in 2024, with the decrease primarily related to a decline in license revenue and service revenue, partially offset by an increase in milestone and royalty revenue and the addition of xPloration revenue.
Research and development expense was $13.9 million for the fourth quarter of 2025, compared with $13.3 million for the same period in 2024, with the increase due to a $3.9 million impairment charge primarily related to certain small molecule ion channel property and equipment, partially offset by lower personnel expenses related to reduced headcount and share-based compensation expense, and lower external expenses associated with legacy small molecule ion channel programs. General and administrative expense was $6.8 million for the fourth quarter of 2025, compared with $7.4 million for the same period in 2024, with the decrease primarily due to lower share-based compensation expense.
Net loss for the fourth quarter of 2025 was $14.2 million, or $0.11 per share, compared with a net loss of $13.1 million, or $0.12 per share, for the same period in 2024.
Full Year 2025 Financial Results
Revenue for 2025 was $18.7 million, compared with $26.4 million for 2024. The decline was primarily due to a decrease in license revenue of $2.5 million and milestone revenue of $1.6 million. Service revenue declined as a result of the completion or discontinuation of certain legacy small molecule ion channel programs. These decreases were offset by the addition of $0.8 million in xPloration revenue reflecting the sale of an instrument and related consumables.
Cost of xPloration revenue was $0.3 million for 2025 and consisted of direct costs associated with the sale of the xPloration instrument and associated consumables. Research and development expense was
$47.8 million for 2025, compared with $55.1 million for 2024, primarily due to lower personnel expenses related to reduced headcount and share-based compensation expense, lower external expenses associated with legacy small molecule ion channel programs and a decline in contract research costs, partially offset by a $3.9 million impairment charge primarily related to certain small molecule ion channel property and equipment. General and administrative expense was $29.2 million for 2025, compared with $30.7 million for 2024 with the decrease primarily due to lower legal fees and share-based compensation expense. Other operating income, net for 2025 was $2.5 million and reflected a gain of $3.0 million from the sale of a small molecule Kv7.2 program partially offset by a $0.3 million increase in contingent liability expense attributed to changes in certain ion channel programs. Other operating income, net during 2024 was $2.4 million and included a $2.5 million reduction in contingent liabilities primarily attributed to changes in small molecule ion channel programs.
Net loss for 2025 was $64.8 million, or $0.57 per share, compared with a net loss of $62.0 million, or $0.61 per share, for the same period in 2024.
As of December 31, 2025, OmniAb had cash, cash equivalents and short-term investments of $54.0 million.
2026 Financial Guidance
OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and costs and operating expenses to be in the range of $80 million to $85 million. Cash costs and operating expenses is expected to be in the range of $50 million to $55 million (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure). The Company expects to end the year with cash and cash equivalents in the range of $30 million to $35 million. The 2026 effective tax rate is expected to be approximately 0%.
Fourth Quarter 2025 and Recent Business Highlights
During the fourth quarter of 2025, OmniAb entered into new license agreements including with Dana Farber Cancer Institute, Mabtrx Biosciences and two global pharmaceutical companies. As of December 31, 2025, the Company had 107 active partners and 407 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.
In December 2025, the Company launched OmniUltra™, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. OmniUltra also enables the isolation of picobodies™, the smallest known natural antibody-derived binding domain (4–6 kDa), which are approximately one-third the size of a nanobody®. OmniUltra is designed to deliver pre-optimized specificity, affinity and structural stability, streamlining hit-to-lead identification. By generating both antibodies and picobodies, it is ideal for applications such as bispecifics, multispecifics, CAR-T, radioligands and stand-alone peptide therapeutics.
OmniAb and GSK published a paper titled “Voltage sensor interaction site for a selective small molecule Nav1.1 sodium channel potentiator that enhances firing of fast-spiking interneurons” in the October 2025 edition of Molecular Pharmacology. The paper highlights the potential for Nav1.1 as a therapeutic target for seizure disorders.
Business and partner highlights from the fourth quarter of 2025 and recent weeks included the following:
IMVT-1402 & batoclimab
•The potentially registrational trial with IMVT-1402 in difficult-to-treat rheumatoid arthritis is fully enrolled, with topline data expected in the second half of this year. Topline data from the proof-of-concept trial with IMVT-1402 in cutaneous lupus erythematosus is also expected in the second half of the year.
•Potentially registrational studies with IMVT-1402 in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease remain on track with topline data in each of GD and MG expected in 2027.
•Immunovant anticipates sharing topline data from its two Phase 3 studies evaluating batoclimab as a treatment for active, moderate-to-severe thyroid eye disease in the first half of this year.
TEV- '408
•Topline results of the Phase 1b trial evaluating TEV-'408 for vitiligo are expected in the first half of this year. Topline results of the Phase 2a trial evaluating TEV-'408 for celiac disease are expected in the second half of this year.
•Teva Pharmaceuticals announced a funding agreement with Royalty Pharma of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody TEV-'408 for vitiligo.
Precemtabart tocentecan (M9140)
•Merck KGaA indicated that based on Phase 1 data, it plans to advance precemtabart tocentecan, a novel anti‑CEACAM5 antibody‑drug conjugate with topoisomerase 1 inhibitor payload, to Phase 3 trials in metastatic colorectal cancer, with the study initiation anticipated in 2026.
RNDO-564
•In December 2025, Rondo Therapeutics announced the first patient was dosed in its Phase 1/1b clinical trial evaluating RNDO-564.
Conference Call and Webcast
OmniAb management will host a conference call with accompanying slides today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (800) 549-8228 using the conference ID 62412. Slides, as well as the live and replay webcast, are available at https://investors.omniab.com/investors/events-and-presentations/default.aspx.
About OmniAb®
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly
identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: statements regarding the growth prospects of our business; the potential for later-stage assets to generate milestones and recurring royalty revenue; the ability to add new partners and programs; the ability to maintain a disciplined cost structure; the expected value and performance of our technologies and the opportunities they may create, including OmniUltra; potential contributions to our business by our xPloration partner access program; scientific presentations and clinical and regulatory events of our partners and the timing thereof and their perspectives on and expectations for their product candidates; and our 2026 financial guidance. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future operating results and success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; risks associated with quality and timing in manufacturing our xPloration instruments and related consumables and our reliance on a limited number of third-party manufacturers and suppliers; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; government healthcare reform, legislative measures and regulatory developments in the United States and foreign countries; unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price; we may not achieve our financial guidance; our operating expenses may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses; we may use our capital resources sooner than we expect; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Partner Information
The information in this press release regarding partnered products and programs comes from information publicly released by our partners.
Note Regarding Use of Non-GAAP Financial Measure
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also projected cash costs and operating expenses, which is a non-GAAP financial measure, adjusted to exclude share-based compensation, depreciation and amortization of intangibles. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, OmniAb believes the presentation of projected non-GAAP cash costs and operating expenses, when viewed in conjunction with GAAP figures, provides investors with a more meaningful understanding of future operating performance. Cash costs and operating expense is not intended to be considered in isolation or as a substitute for costs and operating expenses. A reconciliation between projected cash costs and operating expenses and projected GAAP costs and operating expenses is provided later in this press release.
| Contacts: | ||||||||
| OmniAb, Inc. | ||||||||
| investors@OmniAb.com | ||||||||
X @OmniAbTech | ||||||||
| Alliance Advisors IR | ||||||||
| Yvonne Briggs | ||||||||
| ybriggs@allianceadvisors.com | ||||||||
| (310) 691-7100 | ||||||||
[Tables Follow]
OMNIAB, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands, except share and per share data)
| December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 25,524 | $ | 27,598 | |||||||
| Short-term investments | 28,501 | 31,836 | |||||||||
| Accounts receivable, net | 7,390 | 5,272 | |||||||||
| Prepaid expenses and other current assets | 3,926 | 3,432 | |||||||||
| Total current assets | 65,341 | 68,138 | |||||||||
| Intangible assets, net | 125,149 | 138,060 | |||||||||
| Goodwill | 83,979 | 83,979 | |||||||||
| Property and equipment, net | 9,428 | 15,492 | |||||||||
| Operating lease right-of-use assets | 15,545 | 17,789 | |||||||||
| Restricted cash | 560 | 560 | |||||||||
| Other long-term assets | 912 | 1,540 | |||||||||
| Total assets | $ | 300,914 | $ | 325,558 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,879 | $ | 2,297 | |||||||
| Accrued expenses and other current liabilities | 6,291 | 6,141 | |||||||||
| Current contingent liabilities | 1,044 | 531 | |||||||||
| Current deferred revenue | 3,161 | 2,337 | |||||||||
| Current operating lease liabilities | 3,879 | 3,782 | |||||||||
| Total current liabilities | 16,254 | 15,088 | |||||||||
| Long-term contingent liabilities | 315 | 953 | |||||||||
| Deferred income taxes, net | 785 | 2,314 | |||||||||
| Long-term operating lease liabilities | 16,455 | 19,382 | |||||||||
| Long-term deferred revenue | — | 117 | |||||||||
| Other long-term liabilities | 78 | 86 | |||||||||
| Total liabilities | 33,887 | 37,940 | |||||||||
Stockholders’ equity: | |||||||||||
Preferred stock, $0.0001 par value; 100,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | |||||||||
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2025 and December 31, 2024; 144,308,383 and 121,599,488 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 14 | 12 | |||||||||
| Additional paid-in capital | 433,180 | 388,979 | |||||||||
| Accumulated other comprehensive income | 12 | 27 | |||||||||
| Accumulated deficit | (166,179) | (101,400) | |||||||||
| Total stockholders’ equity | 267,027 | 287,618 | |||||||||
| Total liabilities and stockholders’ equity | $ | 300,914 | $ | 325,558 | |||||||
OMNIAB, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||
| License and milestone revenue | $ | 5,892 | $ | 8,650 | $ | 9,771 | $ | 13,866 | |||||||||||||||
| Service revenue | 2,236 | 2,533 | 7,263 | 11,949 | |||||||||||||||||||
| xPloration revenue | 30 | — | 754 | — | |||||||||||||||||||
| Royalty revenue | 218 | (379) | 878 | 576 | |||||||||||||||||||
| Total revenue | 8,376 | 10,804 | 18,666 | 26,391 | |||||||||||||||||||
| Costs and operating expenses: | |||||||||||||||||||||||
| Cost of xPloration revenue | 9 | — | 303 | — | |||||||||||||||||||
| Research and development | 13,909 | 13,306 | 47,754 | 55,110 | |||||||||||||||||||
| General and administrative | 6,839 | 7,360 | 29,215 | 30,741 | |||||||||||||||||||
| Amortization of intangibles | 3,228 | 6,059 | 12,912 | 17,407 | |||||||||||||||||||
Other operating expense (income), net | 157 | (41) | (2,549) | (2,365) | |||||||||||||||||||
| Total costs and operating expenses | 24,142 | 26,684 | 87,635 | 100,893 | |||||||||||||||||||
| Loss from operations | (15,766) | (15,880) | (68,969) | (74,502) | |||||||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||
| Interest income | 1,225 | 655 | 2,660 | 3,106 | |||||||||||||||||||
Other income (expense), net | (5) | 2 | 15 | (15) | |||||||||||||||||||
| Total other income (expense), net | 1,220 | 657 | 2,675 | 3,091 | |||||||||||||||||||
| Loss before income taxes | (14,546) | (15,223) | (66,294) | (71,411) | |||||||||||||||||||
| Income tax benefit | 367 | 2,155 | 1,515 | 9,378 | |||||||||||||||||||
| Net loss | $ | (14,179) | $ | (13,068) | $ | (64,779) | $ | (62,033) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.11) | $ | (0.12) | $ | (0.57) | $ | (0.61) | |||||||||||||||
| Weighted-average shares outstanding, basic and diluted | 127,789 | 104,795 | 113,635 | 102,365 | |||||||||||||||||||
OMNIAB, INC.
RECONCILIATION OF GAAP COSTS AND OPERATING EXPENSES TO NON-GAAP CASH COSTS AND OPERATING EXPENSES
(in millions)
| 2026 Forecast | |||||
| GAAP costs and operating expenses | $80 to $85 | ||||
| Less: Share-based compensation | 15 | ||||
| Less: Depreciation and amortization | 15 | ||||
| Non-GAAP cash costs and operating expenses | $50 to $55 | ||||
FAQ
How did OmniAb (OABI) perform financially in full-year 2025?
OmniAb reported 2025 revenue of $18.7 million, down from $26.4 million in 2024, and a net loss of $64.8 million, or $0.57 per share. Lower license, milestone and service revenue drove the decline, partly offset by xPloration and royalty revenue.
What guidance did OmniAb (OABI) give for its 2026 revenue and expenses?
For 2026, OmniAb expects $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses. It targets non‑GAAP cash costs of $50–$55 million, reflecting the exclusion of share-based compensation and depreciation and amortization from this measure.
What is OmniAb’s cash position and 2026 year-end cash outlook?
As of December 31, 2025, OmniAb held $54.0 million in cash, cash equivalents and short-term investments. The company expects to end 2026 with $30–$35 million in cash and cash equivalents, based on its revenue and cost guidance and projected cash operating expenses.
How many partners and active programs does OmniAb (OABI) have?
As of December 31, 2025, OmniAb reported 107 active partners and 407 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized. This diversified partner base underpins potential future milestones and royalty revenue across multiple therapeutic areas.
What is OmniUltra™, and why is it important for OmniAb (OABI)?
OmniUltra™ is described as the industry’s first transgenic chicken expressing ultralong CDRH3 domains on a human antibody framework. It can generate both antibodies and tiny “picobodies™,” supporting bispecifics, CAR-T, radioligands and peptide therapeutics, enhancing OmniAb’s ability to attract and serve discovery partners.
What key partner clinical milestones involving OmniAb-derived assets are highlighted?
The company notes expected topline IMVT‑1402 data in difficult-to-treat rheumatoid arthritis and cutaneous lupus in the second half of the year, batoclimab Phase 3 data in thyroid eye disease in the first half, TEV‑'408 trials in vitiligo and celiac disease in 2026, and a planned Phase 3 start for precemtabart tocentecan in metastatic colorectal cancer in 2026.